<DOC>
	<DOCNO>NCT00814541</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , doxorubicin dexamethasone , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) together bortezomib may kill cancer cell . PURPOSE : This phase II trial study well give bortezomib together doxorubicin dexamethasone work treat patient multiple myeloma relapse responded treatment . PATIENT POPULATION : Patients relapse refractory multiple myeloma require therapy invite participate study . Eligible patient &gt; 18 year old able give fully inform consent . Patients must Performance Score ( PS ) 0-3 ( ECOG ) , measurable serum and/or urine paraprotein , serum free light chain , bilirubin value le one half time upper limit normal ALT/AST value less two half time upper limit normal . Patients non-secretory multiple myeloma exclude study .</brief_summary>
	<brief_title>PAD . ICORG 05-01 , V11</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess response ( partial complete response ) patient relapse refractory multiple myeloma receive bortezomib , doxorubicin hydrochloride , dexamethasone ( PAD ) prior treatment maximum 6 course vincristine , doxorubicin , dexamethasone ( VAD ) VAD-like regimen . Secondary - To assess safety toxicity PAD therapy patient . - To determine progression-free survival overall survival patient . - To compare original response VAD response obtain PAD assess percent fall paraprotein Bence Jones Protein , low level abnormal protein achieve , duration response patient . OUTLINE : This multicenter study . STUDY DESIGN &amp; METHODOLOGY : This non-randomised , open label phase II trial patient relapse refractory multiple myeloma . Patients treat : Bortezomib 1.3mg/m^2 bolus IV injection day 1 , 4 , 8 &amp; 11 + Dexamethasone 40mg po day 1 , 2 , 3 , 4 + Doxorubicin 9mg/m^2/day IV continuous infusion day 1 - 4 . In addition , first cycle , Dexamethasone also give 40mg po day 8 - 11 15 - 18 . Each treatment regimen continue minimum four - six - cycle 21 day ( maximum response 1 cycle ) . This study plan recruit total 69 patient 8 centre Ireland UK . Patients enrol three group 23 patient : - Relapsed patient , previously treat VAD VAD like regimen ( VAMP , C-VAMP Z-Dex examples VAD like therapy ) autologous transplant least 1 year previously . Patients may proceed directly PAD therapy maximum one line therapy PAD . - Relapsed patient , previously treat VAD VAD-like regimen autologous transplantation achieve least PR ( Appendix A ) . Patients may proceed directly PAD therapy maximum two line therapy PAD . - Patients refractory ( MR , NC PD ) VAD VAD-like therapy . Patients proceed directly PAD therapy . Patients NC PD may proceed PAD minimum two cycle VAD VAD-like therapy minimum 4 cycle , MR. After completion study treatment , patient follow every 2 month 1 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion criterion : Each patient must meet follow inclusion criterion enrol study : 1 . Patients age least 18 year MM require therapy relapse refractory disease . 2 . Previous VAD VADlike therapy ( maximum 6 course standard VAD ) . Subgroup allocation show 4.1 3 . Measurable serum and/or urine paraprotein , serum free light chain 4 . Performance Status ( PS ) 03 ( ECOG see Appendix B ) 5 . Serum bilirubin value &lt; 1.5 time upper limit normal 6 . Serum ALT/AST value &lt; 2.5 time upper limit normal 7 . Able give inform consent Exclusion criterion : Patients meet follow exclusion criterion enrol study : 1 . Females childbearing potential without negative pregnancy test , immediately prior start PAD therapy and/or unwilling use barrier contraceptive precaution throughout study pregnant breastfeed 2 . Men partner child bear potential unwilling use medically acceptable form contraception 3 . Patients nonsecretory MM measurable elevation serum free light chain 4 . Performance status 4 ( ECOG ) 5 . Patient platelet count &lt; 75 x 10^9/L within 14 day enrolment 6 . Patient absolute neutrophil count &lt; 1.0 x 10^9/L within 14 day enrolment 7 . Patient serum creatinine &gt; 400 micromol/l time enrolment 8 . Patient Grade 2 great Grade 2 peripheral neuropathy neuropathic pain define NCI Common Terminology Criteria Adverse Events version 3.0 ( CTCAE ) within 14 day enrolment 9 . Cardiac ejection fraction &lt; 40 % echocardiography MUGA scan 10 . Known HIV seropositivity ( obligatory test necessary ) 11 . Known Hepatitis B C ( obligatory test necessary ) 12 . Patients receive one autologous transplant 13 . Use investigational drug within 4 week prior enrolment patient schedule receive investigational drug course study 14 . Previous Bortezomib therapy 15 . Patients medical psychiatric condition , opinion investigator , contraindicate patient 's participation study 16 . Previous concurrent malignancy sit , exception appropriately treat localized epithelial skin cervical cancer . Patients remote history ( &gt; 5 year ) cure tumour may enter 17 . Plasma exchange within 21 day enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>